Table 2.

Baseline patient characteristics by treatment group.

	No HDMTX (n = 160)	HDMTX (n = 66)	P
Age, mean (SD), y	64.2 ± 10.5	59.8 ± 11.4	0.006
Male	86 (53.8%)	34 (51.5%)	0.760
Elevated LDH	142 (88.8%)	61(92.4%)	0.406
Stage 3 or 4	153 (95.6)	59 (89.4)	0.077
EN site ≥1	96 (60%)	61 (92%)	<0.001
EN site involvement
Bone marrow	65 (40.6%)	26 (39.4%)	0.862
Kidney/adrenal	44 (27.5%)	14 (21.2%)	0.325
Testis	4 (2.5%)	2 (3.0%)	0.822
Breast	1 (0.6%)	3 (4.5%)	0.042
CNS-IPI			0.277
Low	6 (3.8%)	5 (7.6%)
Intermediate	15 (9.4%)	9 (13.6%)
High	139 (86.9%)	52 (78.8)
Double hit	7 (4.4%)	3 (4.5%)	0.955

Data are n (%), unless otherwise stated. LDH lactate dehydrogenase, EN extranodal, IT intrathecal, HDMTX high-dose methotrexate.